T1Detect (Breakthrough T1D at-home autoantibody screening)
Breakthrough T1D (formerly JDRF), with screening performed by Enable Biosciences
Historical home-screening programme; current ordering unverified.
What it is
A historically offered at-home mail-in screening programme from Breakthrough T1D; current kit ordering and pricing could not be verified. It screens for the islet autoantibodies which precede type 1 diabetes, using a finger-prick dried blood spot measured by Enable Biosciences' agglutination-PCR (ADAP) assay. By opening screening to the general public — not just relatives — it aims to find presymptomatic T1D early enough to prevent diabetic ketoacidosis and connect people to monitoring and the disease-delaying drug teplizumab.
Editorial review: .
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Predictive value: Two or more islet autoantibodies confer ~70% 10-year risk of clinical T1D; single-antibody and antibody-negative results carry much lower, well-quantified risk (Ziegler 2013 JAMA).Read the supporting discussion; this assessment has no individually linked citation.
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Current price, shipping and ordering route not confirmedApproval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
Research status alone does not establish approval, clinical benefit or local availability.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 88 × 25 + 82 × 25 + 40 × 20 + 90 × 15 + 25 × 15 = 6775; divide by total weight 100. Unrounded weighted result: 67.75.
Two or more islet autoantibodies confer ~70% 10-year risk of clinical T1D; single-antibody and antibody-negative results carry much lower, well-quantified risk (Ziegler 2013 JAMA).
Screening-detected children show little DKA at diagnosis (two cases among 280 presymptomatic children in Fr1da); early detection enables metabolic monitoring and identifies stage-2 candidates for teplizumab (Tzield), which delays stage 3 by a median ~2 years; staging is well-defined (Fr1da; TN-10/FDA).
Historically offered beyond relatives; current ordering eligibility is unverified. Home blood-spot sampling has been studied as an acceptable route for general-population screening.
Historical kit design used home capillary blood spots. Studies of other blood-spot screening platforms support convenience and feasibility, but their sensitivity/specificity cannot be assigned to a current T1Detect kit whose specifications and ordering have not been verified.
Current T1Detect kit ordering, price, financial assistance and shipping eligibility could not be verified from a live primary ordering page. Historical launch information is insufficient to promise access today.
The full picture
What T1Detect is
T1Detect was launched as an at-home screening programme using Enable Biosciences testing. The historical launch described general-public access from age 1, US/Puerto Rico shipping and financial assistance.1 Current ordering, price and eligibility could not be confirmed on 16 September 2026, so those launch terms should not be treated as a current offer. The former programme landing page returned 404 during this review; the launch announcement remains historical evidence. For a verified US research-screening route, see ASK, which currently includes children and adults.
SCREENING: what is measured and why it matters
T1D begins years before diagnosis, when the immune system makes islet autoantibodies against insulin-producing cells. Common islet-autoantibody targets include GAD (GADA), islet antigen-2 (IA-2A), insulin (IAA) and zinc-transporter-8 (ZnT8A).2 The current T1Detect test panel could not be verified from a live ordering page. Researchers describe T1D in stages: stage 1 is two or more autoantibodies with normal blood sugar; stage 2 adds abnormal ("dysglycemic") blood sugar; stage 3 is clinical diabetes with symptoms.2
The number of autoantibodies is a powerful predictor. In a landmark pooled study, children with two or more islet autoantibodies had a ~70% risk of clinical T1D within 10 years, whereas a single autoantibody carried ~15% 10-year risk and none carried ~0.4%.3 This is why finding multiple autoantibodies is so meaningful.
Why screen at all? The biggest immediate payoff is avoiding diabetic ketoacidosis (DKA), a dangerous and sometimes fatal way T1D often announces itself. In Germany's Fr1da public-health screening of 90,632 young children, DKA at diagnosis was rare — two cases among 280 children with presymptomatic T1D.4 Early knowledge also enables glucose monitoring, education, and access to clinical trials and therapy.4
The home dried-blood-spot approach is supported by validation and acceptability studies on other screening platforms. These reported sensitivity around 85–89% and specificity around 97–100%, and convenient self-collection. Those figures are not a validated performance specification for a currently available T1Detect kit.56 Australia's Type1Screen program screens for islet autoantibodies using in-home blood-spot sampling.7
THERAPY: what a positive result unlocks
T1Detect is a gateway, not a treatment. A positive result is confirmed with standard testing and triggers monitoring and referral. For people who reach stage 2, there is now an approved disease-modifying drug: teplizumab (Tzield), an anti-CD3 monoclonal antibody. In the pivotal TN-10 trial (76 participants, age 8-49), a single 14-day course delayed progression to clinical (stage 3) T1D by a median of roughly two years versus placebo, and the FDA approved it on 17 November 2022 to delay stage 3 T1D in people aged 8 and older with stage 2 disease.8 Screening is what makes a person eligible to benefit, since you can only be treated at stage 2 if you have been found.
What's coming
The direction of travel is toward broader, earlier, cheaper detection. General-population screening with home blood-spot assays has been validated as an alternative to serum,5 including through Australia's Type1Screen program.7 On the therapy side, the FDA extended teplizumab's stage-2 delay indication down to age 1 in 2026, which — paired with available screening pathways — widens the window in which early detection changes outcomes.8
Coming soon
- →Verification of a current T1Detect ordering route, price and eligibility
Sources
- [1]
Breakthrough T1D (JDRF). JDRF Launches First Mass Screening Program for Early-Stage Type 1 Diabetes (T1D) Detection. Breakthrough T1D press release (2020). https://www.breakthrought1d.org/for-the-media/press-releases/jdrf-launches-first-mass-screening-program-for-early-stage-type-1-diabetes-t1d-detection/
- [2]
Insel RA, Dunne JL, Atkinson MA, et al. Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care (2015). https://doi.org/10.2337/dc15-1419
- [3]
Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA (2013). https://doi.org/10.1001/jama.2013.6285
- [4]
Ziegler AG, Kick K, Bonifacio E, et al. Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany (Fr1da). JAMA (2020). https://doi.org/10.1001/jama.2019.21565
- [5]
Faustini SE, Quinn LM, Hoque M, et al. Establishing the performance and acceptability of dried blood spot sampling to screen for islet-specific autoantibodies. Diabet Med (2025). https://doi.org/10.1111/dme.70071
- [6]
Sing ABE, Naselli G, Huang D, et al. Feasibility and Validity of In-Home Self-Collected Capillary Blood Spot Screening for Type 1 Diabetes Risk. Diabetes Technol Ther (2024). https://doi.org/10.1089/dia.2023.0345
- [7]
Wentworth JM, Sing ABE, Naselli G, et al. Islet Autoantibody Screening Throughout Australia Using In-Home Blood Spot Sampling: 2-Year Outcomes of Type1Screen. Diabetes Care (2025). https://doi.org/10.2337/dc24-2443
- [8]
Sanofi / U.S. prescribing information. TZIELD (teplizumab-mzwv) (initial U.S. approval 2022; stage-2 indication extended to age 1+ in 2026). https://products.sanofi.us/tzield/tzield.pdf